Establishment Labs Reports Strong Q4 2025 Earnings and Optimistic 2026 Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 27 2026
0mins
Source: seekingalpha
Establishment Labs Holdings Inc. shares rose 4.44% as the company reached a 52-week high.
The strong performance was driven by the release of their Q4 2025 earnings report, which highlighted a 45.2% year-over-year revenue growth to $64.6 million, with U.S. Motiva sales contributing significantly. The company also reported a gross margin improvement to 70.5% and provided an optimistic revenue guidance for 2026, projecting between $264 million and $266 million, indicating sustained growth potential.
This positive financial performance reflects the company's effective cost management and operational efficiency, alongside a robust market demand for their products, positioning Establishment Labs for continued success in the upcoming year.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ESTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ESTA
Wall Street analysts forecast ESTA stock price to fall
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 89.230
Low
75.00
Averages
82.88
High
90.00
Current: 89.230
Low
75.00
Averages
82.88
High
90.00
About ESTA
Establishment Labs Holdings Inc. is Costa Rica-based medical technology and aesthetics company that is focused on women's health reconstruction market. The Company is engaged in the designing, developing, manufacturing and marketing of product portfolio consisting of silicone-filled breast and body shaping implants. The main activities are conducted at two manufacturing facilities in Costa Rica including Motiva Implants brand sold in over 80 countries globally through a combination of distributors and direct sales to customers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Conexeu Sciences Targets GLP-1 Aesthetics Market with Innovative Platform
- Market Validation: Galderma's presentation of clinical data on its injectables (Sculptra, Restylane) addressing medication-induced facial volume loss signifies that the 'Ozempic face' category has gained formal recognition, catalyzing rapid growth in the aesthetics industry.
- Surge in Patient Demand: In 2024, U.S. plastic surgeons treated over 837,000 GLP-1 patients, indicating a swift rise in demand for facial restoration, which highlights the substantial potential and business opportunities within this emerging market.
- Technological Innovation: Conexeu's CXU™ platform features a thermosensitive collagen scaffold designed for tissue regeneration rather than mere filling, with a targeted FDA 510(k) submission planned for early 2027, which could open new market avenues for the company if successful.
- Competitive Landscape: As a newly public entity, Conexeu faces competition from established players like Galderma, yet its unique regenerative technology may allow it to carve out a niche in the rapidly expanding aesthetics market.
See More
Establishment Labs to Join Russell 2000 Index
- Inclusion in Russell 2000: Establishment Labs (ESTA) will be added to the US small-cap Russell 2000 Index as part of the 2026 Russell indexes reconstitution, effective June 29, 2026, which is expected to enhance the company's market visibility and attract investor interest.
- Revenue Forecast Increase: The company targets a revenue range of $266.5 million to $268.5 million for 2026, reflecting a rise in minimally invasive revenue forecasts exceeding $35 million, indicating strong growth potential in the medical device market.
- Quant Rating Improvement: Seeking Alpha's Quant Rating highlights Establishment Labs as a strong performer in foreign healthcare, further boosting investor confidence and potentially attracting more institutional investors to the stock.
- Historical Earnings Data: The historical earnings data for Establishment Labs provides crucial financial context for investors, aiding in the assessment of the company's long-term growth potential and market performance, which will play a key role in future investment decisions.
See More
Conexeu Sciences Expands Board to Support Commercialization Efforts
- Board Expansion: On June 15, 2026, Conexeu Sciences Inc. expanded its board from six to nine members, with new directors primarily from Fortune 500 companies, signaling the company's ambition to transition its cutting-edge tissue regeneration technology into a viable business.
- Executive Appointment: Co-founder David Bogart was promoted to Chief Commercial Officer, overseeing over $75 million in capital formation, indicating Conexeu's focus on commercial strategy and market outreach to lay the groundwork for future growth.
- Technology Platform: Conexeu's CXU™ platform is a bioregenerative extracellular matrix that rapidly transitions into a stable gel scaffold at body temperature, expected to target multiple billion-dollar markets including advanced wound care and medical aesthetics, showcasing its broad market potential.
- Market Outlook: With an aging population and the diabetes epidemic, the field of tissue regeneration is experiencing strong market momentum, and while Conexeu faces challenges from larger competitors, its unique technology and leadership team position it well for future success.
See More
Rice Hall James Reduces Stake in Establishment Labs
- Share Reduction Transaction: Rice Hall James & Associates sold 102,885 shares of Establishment Labs in Q1 2026, valued at approximately $7.03 million, indicating a cautious outlook on the company's future growth potential.
- Holding Proportion Change: Following the sale, Rice Hall James's stake in Establishment Labs decreased to 548,674 shares, representing 1.73% of its reportable assets under management, reflecting a diminished confidence in the stock.
- Company Financial Overview: As of May 14, 2026, Establishment Labs' stock price was $69.80, up 91.4% over the past year, despite a net loss of $43.74 million, indicating strong market demand and revenue growth.
- Investor Risk Advisory: While Establishment Labs is experiencing rapid growth in the aesthetic surgery market, it faces cash flow pressures and regulatory challenges, making it suitable for growth-oriented investors willing to accept volatility, while conservative investors may find it unsuitable.
See More
Rice Hall James Sells ESTA Shares Worth $7.03 Million
- Share Sale Details: On May 15, 2026, Rice Hall James & Associates sold 102,885 shares of Establishment Labs (NASDAQ:ESTA) for an estimated $7.03 million, reflecting the fund's strategy to reduce its position during the first quarter.
- Quarter-End Position Value: At quarter-end, the fund held 548,674 shares of ESTA valued at $31.15 million, indicating that despite the reduction, ESTA still represents 1.73% of the fund's total assets under management.
- Market Performance Analysis: Establishment Labs' stock surged approximately 100% over the past year, and this sale appears to be profit-taking, reflecting investors' balancing of confidence in future growth against inherent risks.
- Investor Risk Advisory: While Establishment Labs is rapidly growing in the aesthetic surgery market, it remains unprofitable and faces cash burn and regulatory pressures, making it suitable for growth-oriented investors who can tolerate volatility.
See More
Conexeu Sciences Inc. Goes Public, Pioneering a New Era in Regenerative Medicine
- IPO Milestone: Conexeu Sciences Inc. successfully debuted on Nasdaq on May 21, 2026, with 25,269,996 shares outstanding and a fully diluted total of 35,238,222 shares, marking a significant advancement in regenerative medicine and enhancing its market competitiveness.
- Innovative Product Launch: The company unveiled its 3D bioprinted regenerative breast matrix, B.R.E.A.S.T.™, designed to provide a temporary scaffold for patients post-mastectomy, targeting over 100,000 women annually who opt out of reconstruction, thus opening a larger market opportunity.
- Platform Advantage: Conexeu's CXU™ platform can be applied across multiple tissue regeneration products, streamlining product development processes and targeting multi-billion-dollar markets in wound care, periodontal applications, and facial contouring, indicating vast market potential.
- Regulatory Strategy: The company plans to submit a 510(k) application in early 2027, transitioning its products from investigational to commercial status, further solidifying its leadership position in the regenerative medicine sector.
See More
Conexeu Sciences Targets GLP-1 Aesthetics Market with Innovative Platform
- Market Validation: Galderma's presentation of clinical data on its injectables (Sculptra, Restylane) addressing medication-induced facial volume loss signifies that the 'Ozempic face' category has gained formal recognition, catalyzing rapid growth in the aesthetics industry.
- Surge in Patient Demand: In 2024, U.S. plastic surgeons treated over 837,000 GLP-1 patients, indicating a swift rise in demand for facial restoration, which highlights the substantial potential and business opportunities within this emerging market.
- Technological Innovation: Conexeu's CXU™ platform features a thermosensitive collagen scaffold designed for tissue regeneration rather than mere filling, with a targeted FDA 510(k) submission planned for early 2027, which could open new market avenues for the company if successful.
- Competitive Landscape: As a newly public entity, Conexeu faces competition from established players like Galderma, yet its unique regenerative technology may allow it to carve out a niche in the rapidly expanding aesthetics market.
See More
Establishment Labs to Join Russell 2000 Index
- Inclusion in Russell 2000: Establishment Labs (ESTA) will be added to the US small-cap Russell 2000 Index as part of the 2026 Russell indexes reconstitution, effective June 29, 2026, which is expected to enhance the company's market visibility and attract investor interest.
- Revenue Forecast Increase: The company targets a revenue range of $266.5 million to $268.5 million for 2026, reflecting a rise in minimally invasive revenue forecasts exceeding $35 million, indicating strong growth potential in the medical device market.
- Quant Rating Improvement: Seeking Alpha's Quant Rating highlights Establishment Labs as a strong performer in foreign healthcare, further boosting investor confidence and potentially attracting more institutional investors to the stock.
- Historical Earnings Data: The historical earnings data for Establishment Labs provides crucial financial context for investors, aiding in the assessment of the company's long-term growth potential and market performance, which will play a key role in future investment decisions.
See More
Conexeu Sciences Expands Board to Support Commercialization Efforts
- Board Expansion: On June 15, 2026, Conexeu Sciences Inc. expanded its board from six to nine members, with new directors primarily from Fortune 500 companies, signaling the company's ambition to transition its cutting-edge tissue regeneration technology into a viable business.
- Executive Appointment: Co-founder David Bogart was promoted to Chief Commercial Officer, overseeing over $75 million in capital formation, indicating Conexeu's focus on commercial strategy and market outreach to lay the groundwork for future growth.
- Technology Platform: Conexeu's CXU™ platform is a bioregenerative extracellular matrix that rapidly transitions into a stable gel scaffold at body temperature, expected to target multiple billion-dollar markets including advanced wound care and medical aesthetics, showcasing its broad market potential.
- Market Outlook: With an aging population and the diabetes epidemic, the field of tissue regeneration is experiencing strong market momentum, and while Conexeu faces challenges from larger competitors, its unique technology and leadership team position it well for future success.
See More
Rice Hall James Reduces Stake in Establishment Labs
- Share Reduction Transaction: Rice Hall James & Associates sold 102,885 shares of Establishment Labs in Q1 2026, valued at approximately $7.03 million, indicating a cautious outlook on the company's future growth potential.
- Holding Proportion Change: Following the sale, Rice Hall James's stake in Establishment Labs decreased to 548,674 shares, representing 1.73% of its reportable assets under management, reflecting a diminished confidence in the stock.
- Company Financial Overview: As of May 14, 2026, Establishment Labs' stock price was $69.80, up 91.4% over the past year, despite a net loss of $43.74 million, indicating strong market demand and revenue growth.
- Investor Risk Advisory: While Establishment Labs is experiencing rapid growth in the aesthetic surgery market, it faces cash flow pressures and regulatory challenges, making it suitable for growth-oriented investors willing to accept volatility, while conservative investors may find it unsuitable.
See More
Rice Hall James Sells ESTA Shares Worth $7.03 Million
- Share Sale Details: On May 15, 2026, Rice Hall James & Associates sold 102,885 shares of Establishment Labs (NASDAQ:ESTA) for an estimated $7.03 million, reflecting the fund's strategy to reduce its position during the first quarter.
- Quarter-End Position Value: At quarter-end, the fund held 548,674 shares of ESTA valued at $31.15 million, indicating that despite the reduction, ESTA still represents 1.73% of the fund's total assets under management.
- Market Performance Analysis: Establishment Labs' stock surged approximately 100% over the past year, and this sale appears to be profit-taking, reflecting investors' balancing of confidence in future growth against inherent risks.
- Investor Risk Advisory: While Establishment Labs is rapidly growing in the aesthetic surgery market, it remains unprofitable and faces cash burn and regulatory pressures, making it suitable for growth-oriented investors who can tolerate volatility.
See More
Conexeu Sciences Inc. Goes Public, Pioneering a New Era in Regenerative Medicine
- IPO Milestone: Conexeu Sciences Inc. successfully debuted on Nasdaq on May 21, 2026, with 25,269,996 shares outstanding and a fully diluted total of 35,238,222 shares, marking a significant advancement in regenerative medicine and enhancing its market competitiveness.
- Innovative Product Launch: The company unveiled its 3D bioprinted regenerative breast matrix, B.R.E.A.S.T.™, designed to provide a temporary scaffold for patients post-mastectomy, targeting over 100,000 women annually who opt out of reconstruction, thus opening a larger market opportunity.
- Platform Advantage: Conexeu's CXU™ platform can be applied across multiple tissue regeneration products, streamlining product development processes and targeting multi-billion-dollar markets in wound care, periodontal applications, and facial contouring, indicating vast market potential.
- Regulatory Strategy: The company plans to submit a 510(k) application in early 2027, transitioning its products from investigational to commercial status, further solidifying its leadership position in the regenerative medicine sector.
See More
